Communication to Pharmacies: General
- Orden Administrativa Núm. 441 del Departamento de Salud de Puerto Rico
April 2020 - Prior-authorization for hydroxychloroquine and chloroquine follow up after FDA’s drug safety communication
April 2020 - Carta de Clarificación- medicamento clopidorel
April 2020 - Orden Administrativa Núm. 435 del Departamento de Salud de Puerto Rico
April 2020 - Recomendaciones de dispensación
April 2020 - Prior-authorization for hydroxychloroquine and chloroquine
April 2020 - Guía operacional sobre el despacho de medicamentos durante el estado de emergencia debido al COVID-19
March 2020 - Entrega de medicamentos durante el estado de emergencia debido al COVID-19 y la Ley Núm. 19-2020
Marzo 2020
- Despacho de Medicamentos en Situaciones de Emergencia y/o durante Estado de Emergencia – Poveedores Puerto Rico
Marzo 2020 - Comunicado para proveedores sobre Emergencia COVID-19
Marzo 2020 - RE: Carta Normativa ASES 19-0305. Política pública de anti-discrimen a beneficiarios por razón de identidad de género, expresión de género u orientación sexual real o percibida, al solicitar o recibir servicios de salud.
Marzo 2019 - RE: ASES Normative Letter 19-0305. Public policy for non-discrimination to beneficiaries by reason of gender identity, expression of gender or real or perceived sexual orientation, when requesting or receiving health services.
March 2019 - Guía Básica a Proveedores para manejo sensible y adecuado al brindar servicios de salud a beneficiarios LGBTT+
March 2019 - Importance of the credentialization of pharmacies – Puerto Rico
February 2019
Communication to Pharmacies: Safety
- Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication
April 2020 - Ranitidine All Products Safety Communication
April 2020 - EpiPen: Drug Safety Communication
March 2020 - FDA advises patients on use of NSAIDs for COVID-19
March 2020 - Montelukast: Drug Safety Communication
March 2020 - Clozapine: Drug Safety Communication
February 2020 - Rituxan: Drug Safety Communication
January 2020 - Ibrance, Kisqali and Verzenio: Drug Safety Communication
October 2019
- Mavyret™, Zepatier™, and Vosevi™: Drug Safety Communication
September 2019 - Uloric: Drug Safety Communication
March 2019 - Tofacitinib: Drug Safety Communication Update
February 2019
Communication to Pharmacies: Education
- Considerations for pharmacies during COVID-19 pandemic
MAy 2020 - Emergency use authorization for the investigational remdesivir for COVID-19
May 2020 - COVID-19 Questions and Answers (Q&A)
April 2020 - Coronavirus and Hand Sanitizers
April 2020 - Emergency use authorization of medications for certain patients with COVID-19
April 2020 - Potential COVID-19 Treatment Hydroxychloroquine: Access and Safety
March 2020 - New indications and first-time generics approved by the FDA from October 2019 to December 2019
March 2020 - Coronavirus
February 2020
- Update to Guidelines on Community-Acquired Pneumonia
January 2020 - Dry Eye Disease
December 2019 - New indications and first-time generics approved by the FDA from July 2019 to September 2019
November 2019 - Biosimilar Products
October 2019 - CDC, ACIP Flu Vaccine Recommendations for Upcoming Season
September 2019 - AHA, ACC New Clinical Guidelines on Cholesterol
August 2019 - New indications and first-time generics approved by the FDA from April 2019 to June 2019
July 2019 - Proper use of non-prescription decongestant products.
June 2019 - New indications and first-time generics approved by the FDA from January 2019 to March 2019
May 2019 - Administrative Order 402 – Naloxone Sale Without Prescription
April 2019 - Orden Administrativa 402 – Venta de Naloxona sin Receta
Abril 2019 - No link between MMR vaccine and autism
March 2019 - Influenza Clinical Practice Guidelines Update
February 2019 - New indications and first time generic approved by the FDA
January 2019 - New indications and new generic approvals from October to December 2018
January 2019 - New indications and first-time generics approved by the FDA from July 2018 to September 2018
October 2018 - Updated Guidelines for Resistant Hypertension
September 2018 - Medication Disposal
August 2018 - New indications and first-time generics approved by the FDA from January 2018 to June 2018
July 2018 - Updates in the Guidelines for the use of Antiretroviral Agents in Adults and Adolescents Living with HIV
June 2018 - 2017 New Drug Approvals Summary
April 2018 - PCSK9 Inhibitors
March 2018 - ADA 2018 Standards of Care for Diabetes
February 2018 - New AHA-ACC High Blood Pressure Guidelines
January 2018
PharmNotes
Recalls
- Drug Recall: NP Thyroid
May 2020 - Drug Recall: Ketorolac Injection
April 2020 - Drug Recall: Tetracycline Capsules
April 2020 - Drug Recall: Nizatidine Solution
April 2020 - Drug Recall: Ketorolac injection
March 2020 - Drug Recall: Phenytoin Suspension
February 2020 - Drug Recall: Rompe Pecho liq
January 2020 - Drug Recall: Nitzatinine caps
January 2020
- Drug Recall: Lamotrigine tabs
January 2020 - Drug Recall: Mirtazapine tab
January 2020
Join Our Network
- Exception Request Form
- Important Information About Your Appeal Rights
- Concurrent Utilization Review
- Pharmacy Rights and Responsibilities
- Members Rights and Responsibilities
- Pharmacy and Therapeutics Committee
- Pricing Research Request Form
- Prior Authorization Form
- Retrospective Drug Utilization Review Program
- Universal Claim Form
- Pharmacy Credentialing/ Recredentialing
- PharmPix Pharmacy Network Provider Fraud Waste and Abuse (FWA) and General Compliance Training
- 2019 Fraud, Waste and Abuse (FWA) and General Compliance Training Log
- Fraud, Waste and/or Abuse Complaint Form
- PharmPix Contact Information
- Provider Complaint Form
- Pharmacy Contracting
- Pharmacy Credentialing Form
- PharmPix Provider Manual
